Effects of recombinant human endostatin on proliferation, cell cycle and expression of KDR/FIK-1 and VEGF in hemangioma endothelial cells in vitro
- VernacularTitle:重组人血管内皮抑素对体外培养血管瘤内皮细胞增殖、细胞周期及VEGF、KDR／FIK-1表达的影响
- Author:
Jiang CAO
;
Song YU
;
Xin LV
- Publication Type:Journal Article
- Keywords:
hemangioma;
vascular endothelial cells;
recombinant human endostatin;
proliferation;
cell cycle
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(6):31-34
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe inhibitory effect of recombinant human endostatin on the proliferation of vascular tumor endothelial cells and to investigate its possible mechanism.Methods Hemangioma endothelial cells were cultured in vitro and different concentrations of endostatin on hemangioma endothelial cell proliferation inhibition were detected by MTT method.Effect of recombinant human endostatin on endothelial cell cycle was detected by flow cytometry.The expression of VEGF, KDR mRNA in hemangioma endothelial cell were detected by Real-time RT PCR. Results Recombinant human endostatin concentrations in 24 h, 48 h and 72 h after three period during which the hemangioma endothelial cells inhibited significantly( P <0.01 ) , and there was a clear dose dependence, IC50 was 355 μg/mL.Recombinant human vascular endostatin ( 250 μg/mL ) intervented for 24 hours, the proportion of cells in G0/G1 phase(94.23 ±1.66)%, compared with control group (90.63 ±1.14)%, had significantly difference (P<0.05).Compared with the control group, the difference of the expression of vascular endothelial growth factor (VEGF) was statistically significant (P<0.05) as well as Flk-1 (P <0.05).Conclusion Recombinant human endostatin does not only have inhibitory effect of hemangioma endothelial cell cycle, but also can inhibit the expression of VEGF and FLK-1.
